Monitor upcoming Phase 2b data readouts for EVO756 in Q2 and H2 2026 as key catalysts. The strengthened balance sheet supports continued development of both pipeline programs through 2028, reducing near-term dilution risk.
Price Chart
Executive Summary
Evommune reported positive Phase 2a data for EVO301 in atopic dermatitis and advanced its EVO756 program with upcoming data readouts in chronic spontaneous urticaria and AD. The company strengthened its balance sheet with a $125 million private placement, extending cash runway through 2028. Full-year revenue increased 86% YoY to $13.0 million from a collaboration with Maruho, though the company remains unprofitable with a net loss of $68.9 million.
Key Financial Metrics
Key Facts
- Positive top-line Phase 2a data for EVO301 in atopic dermatitis showed 33% placebo-adjusted improvement in EASI and 23% placebo-adjusted IGA 0/1 at week 12
- EVO756 Phase 2b data readouts expected in Q2 2026 for chronic spontaneous urticaria and H2 2026 for atopic dermatitis
- Closed $125 million private placement, extending cash runway through 2028
- Cash, cash equivalents and investments were $216.7 million as of December 31, 2025
- Full-year revenue was $13.0 million (up 86% YoY) from a strategic collaboration with Maruho Co., Ltd.
- Net loss was $68.9 million for the full year 2025 (up from $66.8 million in 2024)
Financial Impact
Revenue increased 86% YoY to $13.0 million, net loss widened to $68.9 million, cash position strengthened to $216.7 million plus $125 million from private placement
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| License revenue | $13.0M | +85.7% |
Risk Factors
- Clinical trial results may not be replicated in larger studies
- Increased R&D expenses could further widen losses
- Dependence on successful clinical development for future value creation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-093920 |
| Document: evmn-20260305.htm | 0001193125-26-093920 |
| Document: evmn-ex99_2.htm | 0001193125-26-093920 |
| Document: 0001193125-26-093920-index-headers.html | 0001193125-26-093920 |
| Document: 0001193125-26-093920-index.html | 0001193125-26-093920 |
| Document: 0001193125-26-093920.txt | 0001193125-26-093920 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $7.21 | awaiting T+60 | — | $5.16 (−28.43%) |
Sep 15, 2026 6w ago | 8-K | $9.99 | awaiting T+60 | — | $5.16 (−48.35%) |
Jul 30, 2026 12w ago | 8-K | $11.35 $5.10 | ▼ −55.07% | ▼ −57.53% | $5.16 (−54.54%) |
Jul 10, 2026 15w ago | Insider Cluster | $12.10 $6.61 | ▼ −45.37% | ▼ −49.37% | $5.16 (−57.36%) |
Jun 29, 2026 17w ago | 8-K | $15.05 $9.60 | ▲ +36.21% | ▲ +40.60% | $5.16 (+65.71%) |
Jun 24, 2026 17w ago | Insider Cluster | $24.13 $9.65 | ▼ −60.01% | ▼ −63.74% | $5.16 (−78.62%) |
Jun 3, 2026 20w ago | Insider Cluster | $20.69 $13.23 | ▲ +36.06% | ▲ +37.94% | $5.16 (+75.06%) |
Jun 2, 2026 21w ago | 144 | $19.73 $13.48 | ▼ −31.68% | ▼ −34.18% | $5.16 (−73.85%) |
Jun 1, 2026 21w ago | Insider Cluster | $19.82 $14.11 | ▼ −28.81% | ▼ −29.93% | $5.16 (−73.97%) |
May 28, 2026 21w ago | 144 | $23.23 $13.67 | ▲ +41.15% | ▲ +42.34% | $5.16 (+77.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers